Why Merck & Co. (MRK) Stock Is Up Today

Merck & Co. (MRK) is up 3.5% today. Here is some analysis on what might have caused this price movement. ([merck.com](https://www.merck.com/investor-relations/?utm_source=openai))

Analysis: The move appears tied to a mix of recent regulatory wins, positive late-stage pipeline news, and improving Wall Street sentiment ahead of the company’s August 4, 2026 earnings call. This could also reflect investors giving more credit to Merck’s effort to broaden growth drivers beyond its core oncology franchise. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications?utm_source=openai))

Details:

The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph with enfortumab vedotin on July 10, 2026 for certain adults with muscle-invasive bladder cancer, adding another new use for a key Merck cancer medicine. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications?utm_source=openai))

The FDA also approved a first-line triple-negative breast cancer use for sacituzumab govitecan in combination with pembrolizumab in late June, extending Merck’s oncology reach in another major setting. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line?utm_source=openai))

Merck said on June 22 that tulisokibart met primary and key secondary endpoints in a Phase 3 ulcerative colitis study, which supports the view that its non-oncology pipeline may become a more meaningful contributor over time. ([merck.com](https://www.merck.com/news/mercks-tulisokibart-met-primary-and-key-secondary-endpoints-in-the-phase-3-atlas-uc-induction-only-study-in-patients-with-moderately-to-severely-active-ulcerative-colitis-uc/?utm_source=openai))

Investors also appear to be responding to a more constructive analyst backdrop, with a recent price-target increase ahead of second-quarter results scheduled for August 4. ([ph.investing.com](https://ph.investing.com/news/stock-market-news/guggenheim-raises-merck-stock-price-target-to-145-on-pipeline-outlook-93CH-2488870?utm_source=openai))

Sources:

FDA, Merck, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRK Insider Trading Activity

$MRK insiders have traded $MRK stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $MRK stock by insiders over the last 6 months:

JENNIFER ZACHARY (EVP, General Counsel) has made 0 purchases and 3 sales selling 121,573 shares for an estimated $14,485,690.
ROBERT M DAVIS (Chairman, CEO & President) has made 0 purchases and 2 sales selling 47,434 shares for an estimated $5,599,327.
CAROLINE LITCHFIELD (EVP & CFO) sold 41,997 shares for an estimated $5,023,311
CHIRFI GUINDO (Chief Marketing Officer) has made 0 purchases and 3 sales selling 40,000 shares for an estimated $4,836,339.
RICHARD R. DELUCA (EVP&Pres, Merck Animal Heallth) sold 37,685 shares for an estimated $4,557,024
JOHANNES JACOBUS OOSTHUIZEN (President, U.S. Market) sold 15,000 shares for an estimated $1,827,991
DEAN Y LI (Executive VP & President, MRL) sold 15,087 shares for an estimated $1,791,824
DALTON E. III SMART (SVP Fin. - Global Controller) has made 0 purchases and 2 sales selling 6,400 shares for an estimated $765,920.
DAVID MICHAEL WILLIAMS (EVP,Chief Info&Digital Officer) sold 5,000 shares for an estimated $609,525

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$MRK Hedge Fund Activity

We have seen 1,578 institutional investors add shares of $MRK stock to their portfolio, and 1,540 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 7,007,793 shares (-70.5%) from their portfolio in Q1 2026, for an estimated $841,811,134
BLACKROCK, INC. added 6,734,865 shares (+3.1%) to their portfolio in Q1 2026, for an estimated $809,025,658
UBS GROUP AG removed 5,244,642 shares (-27.3%) from their portfolio in Q1 2026, for an estimated $630,012,620
MILLENNIUM MANAGEMENT LLC removed 4,829,660 shares (-71.0%) from their portfolio in Q1 2026, for an estimated $580,162,907
PRICE T ROWE ASSOCIATES INC /MD/ added 4,289,452 shares (+22.9%) to their portfolio in Q1 2026, for an estimated $515,270,421
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 4,144,192 shares (-93.8%) from their portfolio in Q1 2026, for an estimated $497,821,064
FMR LLC added 3,679,444 shares (+9.0%) to their portfolio in Q1 2026, for an estimated $441,993,210

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MRK Government Contracts

We have seen $6,036,619 of award payments to $MRK over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ERVEBO PROCUREMENT: $2,843,515
VACCINE STORAGE AND ROTATION, 2021-2026: $1,267,628
OR-KLAMATH FALLS FWO-BIOMARK PURCH REQUE: $297,003
E14 IMPERIAL PONDS PIT SCANNER ARRAY: $127,600
EMERGENCY WINREVAIR: $105,209

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$MRK Congressional Stock Trading

Members of Congress have traded $MRK stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $MRK stock by members of Congress over the last 6 months:

REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 02/04.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MRK Price Targets

Multiple analysts have issued price targets for $MRK recently. We have seen 14 analysts offer price targets for $MRK in the last 6 months, with a median target of $140.0.

Here are some recent targets:

Terence Flynn from Morgan Stanley set a target price of $113.0 on 07/09/2026
Mohit Bansal from Wells Fargo set a target price of $150.0 on 07/08/2026
Trung Huynh from RBC Capital set a target price of $142.0 on 07/08/2026
Carter Gould from Cantor Fitzgerald set a target price of $120.0 on 07/06/2026
Louise Chen from Scotiabank set a target price of $155.0 on 06/30/2026
Tim Anderson from B of A Securities set a target price of $141.0 on 06/30/2026
An analyst from CICC set a target price of $138.0 on 06/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.